Trial reportInternational journal of chronic obstructive pulmonary disease2015
Bronchoscopic lung volume reduction by endobronchial valve in advanced emphysema: the first Asian report.
Trial report in International journal of chronic obstructive pulmonary disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01869205 (The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2017Pooled it
- Research Progress and Comparative Evaluation of Three Cutting-Edge Chronic Obstructive Pulmonary Disease Treatment Strategies: Biologics, Bronchoscopic Lung Volume Reduction, and Stem Cell Therapies.International journal of chronic obstructive pulmonary disease · 2026Review
- Endobronchial valves for emphysema and persistent air-leak: 10-year experience in an Asian country.BMC pulmonary medicine · 2024Article
- Endobronchial Valve Treatment of Tuberculous Cavities in Patients with Multidrug-Resistant Pulmonary Tuberculosis: A Randomized Clinical Study.Pathogens (Basel, Switzerland) · 2022Article
- When Treatment of Pulmonary Emphysema with Endobronchial Valves Did Not Work: Evaluation of Quantitative CT Analysis and Pulmonary Function Tests Before and After Valve Explantation.International journal of chronic obstructive pulmonary disease · 2022Article
- Reduction of COPD Hyperinflation by Endobronchial Valves Improves Intercostal Muscle Morphology on Ultrasound.International journal of chronic obstructive pulmonary disease · 2020Article
- Clinical Utility of Quantitative CT Analysis for Fissure Completeness in Bronchoscopic Lung Volume Reduction: Comparison between CT and Chartis™.Korean journal of radiology · 2019Article
- Bronchoscopic lung volume reduction using an endobronchial valve to treat a huge emphysematous bullae: a case report.BMC pulmonary medicine · 2019Article
- Comparison of distinctive models for calculating an interlobar emphysema heterogeneity index in patients prior to endoscopic lung volume reduction.International journal of chronic obstructive pulmonary disease · 2017Article
- Lung perfusion and emphysema distribution affect the outcome of endobronchial valve therapy.International journal of chronic obstructive pulmonary disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEndobronchial valve (EBV) therapy is increasingly being seen as a therapeutic option for advanced emphysema, but its clinical utility in Asian populations, who may have different phenotypes to other ethnic populations, has not been assessed. PATIENTS AND
methodsThis prospective open-label single-arm clinical trial examined the clinical efficacy and the safety of EBV in 43 consecutive patients (mean age 68.4±7.5, forced expiratory volume in 1 second [FEV1] 24.5%±10.7% predicted, residual volume 208.7%±47.9% predicted) with severe emphysema with complete fissure and no collateral ventilation in a tertiary referral hospital in Korea.
resultsCompared to baseline, the patients exhibited significant improvements 6 months after EBV therapy in terms of FEV1 (from 0.68±0.26 L to 0.92±0.40 L; P<0.001), 6-minute walk distance (from 233.5±114.8 m to 299.6±87.5 m; P=0.012), modified Medical Research Council dyspnea scale (from 3.7±0.6 to 2.4±1.2; P<0.001), and St George's Respiratory Questionnaire (from 65.59±13.07 to 53.76±11.40; P=0.028). Nine patients (20.9%) had a tuberculosis scar, but these scars did not affect target lobe volume reduction or pneumothorax frequency. Thirteen patients had adverse events, ten (23.3%) developed pneumothorax, which included one death due to tension pneumothorax.
conclusionEBV therapy was as effective and safe in Korean patients as it has been shown to be in Western countries. (
trial registrationClinicalTrials.gov: NCT01869205).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.